Calaspargase pegol
Asparlas (calaspargase pegol) is an enzyme pharmaceutical. Calaspargase pegol was first approved as Asparlas on 2018-12-20. It is used to treat precursor cell lymphoblastic leukemia-lymphoma in the USA.
| Trade Name | Asparlas |
|---|---|
| Common Name | Calaspargase pegol |
| Indication | precursor cell lymphoblastic leukemia-lymphoma |
| Drug Class | Enzymes; PEGylated compounds |
